Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Meiss

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
International Journal of Cancer|July 8, 2024
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADORegSebastian A Wohlfeil, Leonie Kranzmann, Christel Weiß, et al.
International Journal of Cancer|May 16, 2026
Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in GermanyGlenn Geidel, Theresa Lowinus, Patrick Metzger, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaDirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGKonstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
Oncotarget|May 6, 2017
Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expressionHana Andrlová, Justin Mastroianni, Josef Madl, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesRicarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREGSophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
Nature Immunology|December 20, 2024
Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1<sup>+</sup>CD8<sup>+</sup> T cellsZhen Zhang, Marlene Langenbach, Sagar Sagar, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
International Journal of Cancer|July 8, 2024
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADORegSebastian A Wohlfeil, Leonie Kranzmann, Christel Weiß, et al.
International Journal of Cancer|May 16, 2026
Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in GermanyGlenn Geidel, Theresa Lowinus, Patrick Metzger, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaDirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGKonstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
Oncotarget|May 6, 2017
Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expressionHana Andrlová, Justin Mastroianni, Josef Madl, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesRicarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREGSophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
Nature Immunology|December 20, 2024
Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1<sup>+</sup>CD8<sup>+</sup> T cellsZhen Zhang, Marlene Langenbach, Sagar Sagar, et al.
Pageof 11